TWST — Twist Bioscience Corporation

Summary of Twist Bioscience Q3 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Achieved record revenue of $118.4 million, a 23% year-over-year increase, marking the 14th consecutive quarter of growth.
• Gross Margin: Improved to 52.8%, up 120 basis points sequentially, with 70% of incremental revenue contributing to gross margin.
• Adjusted EBITDA: Reported a loss of $11.3 million, with expectations to reach breakeven in Q4 2026.
• Cash Position: Ended the quarter with $166.8 million in cash and short-term investments.

2. Strategic Updates and Business Highlights

• AI-Enabled Discovery: Recognized as a significant growth driver, with expectations of triple-digit percentage order growth in fiscal 2026 and continued momentum into fiscal 2027.
• Product Development: Launched new offerings, including complex gene synthesis, which has seen early adoption with over 1,800 complex genes ordered.
• Public Health Contributions: Highlighted the role of Twist’s platform in identifying pathogens during outbreaks, showcasing the speed and reliability of their services.
• Customer Engagement: Increased focus on building relationships with customers in AI-drug discovery, leading to more transparency and engagement in their needs.

3. Forward Guidance and Outlook

• Fiscal 2026 Revenue Guidance: Increased to $456 million to $457 million, representing approximately 21% year-over-year growth.
• Q4 2026 Revenue Expectations: Projected revenue of $123 million to $124 million, indicating 25% year-over-year growth.
• Long-Term Growth Potential: Anticipated serviceable addressable market projected to reach $13 billion by 2030.

4. Bad News, Challenges, or Points of Concern

• Sequential Decline in Therapeutics Revenue: Despite strong year-over-year growth, there was a noted sequential decline in therapeutics revenue, raising questions about order dynamics and competitive pressures.
• Competition: Concerns about competitive actions from other vendors, particularly in pricing and capabilities, though management expressed confidence in their unique offerings and customer relationships.
• Operational Costs: Operating expenses increased to $98.7 million, which included one-time costs, though expected reductions in OpEx were noted for Q4.

5. Notable Q&A Insights

• Customer Dynamics: Management indicated that existing customers are increasingly returning for iterative design and new customers are entering the AI-drug discovery space, contributing to confidence in future growth.
• Order to Revenue Conversion: The timeline for AI orders is improving, with better alignment between orders and revenue recognition compared to previous years.
• Academic and Government Revenue Growth: Noted a significant uptick in this segment, attributed to the value proposition resonating in a budget-constrained environment, leading to a 32% year-over-year increase.
• Future Product Mix: Emphasis on expanding capabilities in data characterization and the introduction of proprietary enzymes to enhance workflows in NGS applications.

Overall, Twist Bioscience showcased strong financial performance and strategic positioning in the growing market for AI-enabled drug discovery and diagnostics, while also navigating competitive pressures and operational challenges.